Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eisai Medical Research Inc. |
---|---|
Information provided by: | Eisai Medical Research Inc. |
ClinicalTrials.gov Identifier: | NCT00236197 |
This is a multicenter, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of rabeprazole 10 mg in treating frequent heartburn. The study will last for up to five weeks and consists of the following three phases: a one to two week screening period that includes a one week, single-blind, placebo run-in phase, a two week double-blind, randomized treatment phase, and a one week single-blind, placebo follow-up phase.
Condition | Intervention | Phase |
---|---|---|
Heartburn |
Drug: RABEPRAZOLE SODIUM |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety Study |
Study Start Date: | October 2005 |
Study Completion Date: | June 2008 |
Primary Completion Date: | March 2006 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |
New York Center For Clinical Research | |
Lake Success, New York, United States, 11042 |
Study Director: | Claudio Pasquinelli | Eisai Medical Research Inc. |
Study ID Numbers: | E3810-A001-312 |
Study First Received: | October 10, 2005 |
Last Updated: | June 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00236197 |
Health Authority: | United States: Food and Drug Administration |
Signs and Symptoms Pyrosis Signs and Symptoms, Digestive Heartburn Rabeprazole |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Anti-Ulcer Agents |
Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |